

Table S1 Survival rate by strata

	<30 days	90-day	180-day	1-year	2-year	3-year	3-year*
Group 65-70	88.3	73.4	71.5	71.5	62.2	60.3	84.3
Group ≥70	78.2	65	63	63	52	48.7	77.3
CLUTR 2015-2018	81.45	74.97	72.24	70.11	64.85	61.16	
TTX, recipients ≥65				83		62	
TTX, 2010-2017	95.35	93.44	89.38	84.81	77.15	70.26	
Without cardiac abnormality	87.7	76.7	73.1	64.4	62.7	62.7	
With cardiac abnormality	75	59.1	56.5	56.5	44	44	

* 3-year survival conditioned to 1-year survived

Table S2 Association Between Covariates and Time to Death

Variables	Unadjusted	
	HR(95%CI)	p value
Age group (65-70* vs. ≥ 70)	1.524 (0.925-2.510)	0.098
NYHA Grade IV (No. vs. Yes)	4.80 (2.87, 8.04)	0.000
Chronic steroid use (No. vs. Yes)	3.027 (1.764-5.193)	0.000
Cardiac abnormality (No. vs. Yes)	1.93 (1.16, 3.21)	0.0109
Cardiac disease history, patient-reported (No. vs. Yes)	1.89 (1.14, 3.11)	0.0129
Pulmonary infection need admission (No. vs. Yes)	1.72 (1.03, 2.86)	0.0367
Pretransplant tobacco use (No. vs. Yes)	0.78 (0.48, 1.27)	0.3148
Primary diagnosis(non-Group D vs. Group D)	1.06 (0.61, 1.82)	0.8422
Hypertension (No. vs. Yes)	0.90 (0.53, 1.52)	0.6912
BMI (≥ 20 kg/m ² vs. <20 kg/m ²)	1.17 (0.64, 2.16)	0.6067

Table S3 Comparison of characteristics when considering with or without cardiac abnormality

	Cardiac abnormality (-) N=122	Cardiac abnormality(+) N=44	χ^2	p value
Primary diagnosis, Group D, n(%)	88 (72.1)	31 (70.5)	0.045	0.847
NYHA Grade IV, n(%)	47 (38.5)	12 (27.3)	1.787	0.203
SLLT, n(%)	42 (34.4)	22 (50)	3.311	0.074
Post-LT				
Fungal infection, n(%)	53 (43.4)	25 (56.8)	2.323	0.159
Acute rejection, n(%)	11 (9)	7 (15.7)	1.589	0.257
Valve dysfunction, post-LT, n(%)	31 (25.4)	11 (25)	0.003	1.000
Cardiac Arrhythmia, n(%)	57 (46.7)	30 (68.2)	5.971	0.022
Cerebral dysfunction, n(%)	58 (47.5)	22 (50)	0.078	0.861
PGD (\geq Grade 2 at 72h), n(%)	73 (65.2)	23 (52.3)	2.223	0.147
Reintubation, n(%)	23 (18.9)	9 (20.5)	0.053	0.826
Pleural effusion, n(%)	45 (36.9)	19 (43.2)	0.541	0.475
Pulmonary embolism, n(%)	5 (4.1)	7 (15.9)	6.726	0.016
Acute kidney injury, n(%)	27 (22.1)	19 (43.2)	7.153	0.010